ROKIT’s AI and 3D bioprinting convergence technology has been recognized as an innovative solution to treat chronic wounds such as diabetic foot ulcers.
SEOUL, South Korea, March 15, 2022 /PRNewswire/ — ROKIT Healthcare, a global hyper-personalized organ regeneration company, announced on March 7th that its paper about the “AI and 3D bioprinting convergence technology for regenerative treatments” has been accepted to 2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR).
CVPR is a premier international conference co-hosted by the IEEE and the International Computer Vision Foundation (CVF) since 1983, and is one of the most prestigious venues in computer vision and artificial intelligence with an impact score of 45.17. It is also ranked fourth following Nature, NEJM and Science journals on Google Scholar’s top publications.
The accepted paper is “Generating 3D Bio-Printable Patches Using Round Segmentation and Reconstruction to Treat Diabetic Foot Ulcers,” which remotely creates a 3D model patch from a single photo for wound regeneration using deep learning techniques. ROKIT has explained that this achievement will open a new era of the world’s first AI-powered wound regeneration.
Han Joo Chae, a chief AI officer and vice president, said, “Recently, solving real-world problems applying machine learning techniques is a big topic and ROKIT’s convergence technology has been recognized worldwide in regenerating chronic wounds.” He also added, “As our technology allows consistent and high-quality treatment anywhere in the world, we expect to relieve the pain of patients in medically underserved areas in the future.
ROKIT has recently been recognized for its full-fledged research results in the global market; a paper on preclinical cartilage regeneration conducted by Harvard Medical School has been published in the International Journal of Molecular Science (SCI journal, IF: 5.9).
The company is also speeding up its development of global markets by obtaining global certification and medical device registration of the treatment kits for 3D bioprinters. Last month, the U.S. FDA Class 1 registration of “Dr. INVIVO Scaffold KIT,” which is used for skin and cartilage regeneration, was completed, and this month, it is submitting an FDA track for “Dr. INVIVO Regen KIT,” a fat micronizing tool.
ROKIT has recently added new global contracts such as in Brazil, Thailand, and the Philippines and has signed cumulative distribution contracts worth more than 1.6B USD from November 2020 to the present. The company is also preparing for the future by launching the world’s first organ regeneration device with decellularization and recellularization capabilities last month. ROKIT is preparing for pre-IPO funding, sales growth, and technical documentations to re-challenge the company listing soon.
Donate To The Indian Sun
Dear Reader,The Indian Sun is an independent organisation committed to community journalism. We have, through the years, been able to reach a wide audience especially with the growth of social media, where we also have a strong presence. With platforms such as YouTube videos, we have been able to engage in different forms of storytelling. However, the past few years, like many media organisations around the world, it has not been an easy path. We have a greater challenge. We believe community journalism is very important for a multicultural country like Australia. We’re not able to do everything, but we aim for some of the most interesting stories and journalism of quality. We call upon readers like you to support us and make any contribution. Do make a DONATION NOW so we can continue with the volume and quality journalism that we are able to practice.
Thank you for your support.
Best wishes,
Team The Indian Sun
